TY - JOUR
T1 - EBV and MSI Status in Gastric Cancer
T2 - Does It Matter?
AU - do Nascimento, Catarina Neto
AU - Mascarenhas-Lemos, Luís
AU - Silva, João Ricardo
AU - Marques, Diogo Sousa
AU - Gouveia, Catarina Ferreira
AU - Faria, Ana
AU - Velho, Sónia
AU - Garrido, Rita
AU - Maio, Rui
AU - Costa, Andreia
AU - Pontes, Patrícia
AU - Wen, Xiaogang
AU - Gullo, Irene
AU - Cravo, Marília
AU - Carneiro, Fátima
N1 - Funding Information:
This research was partially co-financed by Hospital da Luz Lisboa under the initiative “Luz Investigação” in the context of the Group GENIUS (Reference LH.INV.F2019015).
PY - 2023/1
Y1 - 2023/1
N2 - We investigated the impactof microsatellite instability (MSI) and Epstein–Barr virus (EBV) status in gastric cancer (GC), regarding response to perioperative chemotherapy (POPChT), overall survival (OS), and progression-free survival (PFS). We included 137 cases of operated GC, 51 of which were submitted to POPChT. MSI status was determined by multiplex PCR and EBV status by EBV-encoded RNA in situ hybridization. Thirty-seven (27%) cases presented as MSI-high, and seven (5.1%) were EBV+. Concerning tumor regression after POPChT, no differences were observed between the molecular subtypes, but females were more likely to respond (p = 0.062). No significant differences were found in OS or PFS between different subtypes. In multivariate analysis, age (HR 1.02, IC 95% 1.002–1.056, p = 0.033) and positive lymph nodes (HR 1.82, IC 95% 1.034–3.211, p = 0.038) were the only prognostic factors for OS. However, females with MSI-high tumors treated with POPChT demonstrated a significantly increased OS compared to females with MSS tumors (p = 0.031). In conclusion, we found a high proportion of MSI-high cases. MSI and EBV status did not influence OS or PFS either in patients submitted to POPChT or surgery alone. However, superior survival of females with MSI-high tumors suggests that sex disparities and molecular classification may influence treatment options in GC.
AB - We investigated the impactof microsatellite instability (MSI) and Epstein–Barr virus (EBV) status in gastric cancer (GC), regarding response to perioperative chemotherapy (POPChT), overall survival (OS), and progression-free survival (PFS). We included 137 cases of operated GC, 51 of which were submitted to POPChT. MSI status was determined by multiplex PCR and EBV status by EBV-encoded RNA in situ hybridization. Thirty-seven (27%) cases presented as MSI-high, and seven (5.1%) were EBV+. Concerning tumor regression after POPChT, no differences were observed between the molecular subtypes, but females were more likely to respond (p = 0.062). No significant differences were found in OS or PFS between different subtypes. In multivariate analysis, age (HR 1.02, IC 95% 1.002–1.056, p = 0.033) and positive lymph nodes (HR 1.82, IC 95% 1.034–3.211, p = 0.038) were the only prognostic factors for OS. However, females with MSI-high tumors treated with POPChT demonstrated a significantly increased OS compared to females with MSS tumors (p = 0.031). In conclusion, we found a high proportion of MSI-high cases. MSI and EBV status did not influence OS or PFS either in patients submitted to POPChT or surgery alone. However, superior survival of females with MSI-high tumors suggests that sex disparities and molecular classification may influence treatment options in GC.
KW - Epstein–Barr virus
KW - females
KW - gastric cancer
KW - gender
KW - microsatellite instability
KW - molecular subtype
KW - neoadjuvant chemotherapy
KW - perioperative chemotherapy predictor
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85145987366&partnerID=8YFLogxK
U2 - 10.3390/cancers15010074
DO - 10.3390/cancers15010074
M3 - Article
C2 - 36612071
AN - SCOPUS:85145987366
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 1
M1 - 74
ER -
